Safety of oral propranolol for the treatment of infantile hemangioma: a systematic review
C Leaute-Labreze, O Boccara… - …, 2016 - publications.aap.org
METHODS: We searched Embase and Medline databases (2007–July 2014) and
unpublished data from the manufacturer of Hemangiol/Hemangeol (marketed pediatric
formulation of oral propranolol; Pierre Fabre Dermatologie, Lavaur, France). Selected
studies included≥ 10 patients treated with oral propranolol for IH and that either reported≥
1 adverse event or effect (AE) or planned to capture AEs. Data capture was standardized
and extracted study design, demographic characteristics, IH characteristics, intervention …
unpublished data from the manufacturer of Hemangiol/Hemangeol (marketed pediatric
formulation of oral propranolol; Pierre Fabre Dermatologie, Lavaur, France). Selected
studies included≥ 10 patients treated with oral propranolol for IH and that either reported≥
1 adverse event or effect (AE) or planned to capture AEs. Data capture was standardized
and extracted study design, demographic characteristics, IH characteristics, intervention …
